Ipsen, PeptiMimesis partner to develop therapeutic peptides in oncology

Ipsen and PeptiMimesis have announced a research partnership for the development of novel therapeutic peptides in oncology.

Through the partnership, the companies will work on moving the project forward towards clinical development.

The partners will develop therapeutic peptides to target a transmembrane receptor that is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation.

Ipsen will combine its expertise in peptide design and development with PeptiMimesis’ knowledge in the identification of transmembrane peptides and intracellular signalling.

"We are convinced that this initial collaboration will pave the way for a series of partnerships, given the tremendous possibilities of targeting transmembrane receptors."

Additionally, Ipsen has an option to acquire the exclusive rights to develop and market the new drug candidates.

PeptiMimesis chairman Pascal Neuville said: "PeptiMimesis is extremely proud that its innovative approach is recognised by Ipsen, a prominent partner in therapeutic peptides.

"We are convinced that this initial collaboration will pave the way for a series of partnerships, given the tremendous possibilities of targeting transmembrane receptors."

Ipsen will finance PeptiMimesis’ research phases, as well as milestone payments associated with the programme. It could also finance PeptiMimesis at development, regulatory and commercial milestones, as well as providing royalty payments on worldwide annual net sales.

PeptiMimesis scientific founder Dominique Bagnard said: "This partnership is the result of more than 15 years of research that reached the validation stage thanks to the support of SATT Conectus.

"Work on the project will now continue in close cooperation between my laboratory, PeptiMimesis, and Ipsen."

PeptiMimesis is a start-up from an INSERM (French National Institute of Health and Medical Research) and Strasbourg University spin-off project, funded by SATT Conectus Alsace.

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield. Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex clarification train. This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.